CAMBRIDGE, England, November 29 /PRNewswire/ -- Astex Therapeutics Ltd. today announced that data on its drug candidates AT9283, AT7519 and AT9311 will be presented at the American Society of Hematology's 49th Annual Meeting and Exposition, 8-11th December 2007, at the Georgia World Congress Center, Atlanta, Georgia.
AT9283 is an inhibitor of the kinases Aurora A, Aurora B, JAK2, BCR-Abl and Flt-3. There is strong evidence for an important role of each of these kinases in the development or progression of a variety of cancers. AT9283 is currently being investigated in three multi-centre clinical trials, including a Phase I/II study in patients with refractory haematological malignancies.
AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs), currently in two multi-centre Phase 1 clinical trials.
AT9311 (also known as NVP-LCQ195) is also an inhibitor of CDKs, but with a pharmacological profile that is markedly different from that of AT7519. Astex is developing AT9311 in collaboration with Novartis.
Astex discovered all of these compounds using its proprietary fragment-based drug discovery platform Pyramid(TM).
"Astex has discovered and is developing a number of products that may have promise in the treatment of a wide range of life-threatening haematological diseases. Together with investigators from the M.D. Anderson Cancer Center and the UAB Comprehensive Cancer Center, we are reporting for the first time that one of these, AT9283, has already shown early signs of clinical efficacy as a single agent in the treatment of advanced refractory AML and CML," said Harren Jhoti, Chief Scientific Officer and Executive Vice President of Astex.
Hagop Kantarjian, Chairman of the Department of Leukemia at M.D.
Anderson, Principal Investigator in the Phase I/II study of AT9283, said,
"We see preliminary evidence of the anti-leukemic activity of AT9283 at
well-tolerated doses in patients with relapsed and refra
|SOURCE Astex Therapeutics|
Copyright©2007 PR Newswire.
All rights reserved